Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
CONVERT trial data demonstrate AeriSeal® System is safe and effective with 77.6% of patients converted from CV+ to CV- 5-year d...
Piper Sandler analyst Jason Bednar maintains Pulmonx (NASDAQ: LUNG) with a Overweight and lowers the price target from $14 t...
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and raises the price target from $15 to $16.
Wells Fargo analyst Larry Biegelsen maintains Pulmonx (NASDAQ:LUNG) with a Equal-Weight and lowers the price target from $14...
Pulmonx (NASDAQ:LUNG) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.44) by 11...
Lake Street analyst Frank Takkinen initiates coverage on Pulmonx (NASDAQ:LUNG) with a Buy rating and announces Price Target ...
Canaccord Genuity analyst Jon Young maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $16 to $15.
